IONS241115C55000
- 0.00
- 0.000.00%
Ionis Pharmaceuticals Newsroom
Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $62
10 Health Care Stocks Whale Activity In Today's Session
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Lagging The Industry But So Is The Business
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $45 to $77
Ionis Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Ionis Pharmaceuticals: Promising Pipeline and Strategic Milestones Drive Buy Rating
Where Ionis Pharmaceuticals Stands With Analysts
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $51 to $77
Ionis to Present at Upcoming Investor Conferences
RBC Capital Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals Price Target Lowered to $77 From $82 at Wells Fargo
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT) and Cytokinetics (CYTK)
Ionis Pharmaceuticals (IONS) Gets a Hold From Barclays
Ionis Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Ionis Pharmaceuticals: Strategic Developments and Robust Pipeline Justify Buy Rating
Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript Summary
Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript
Express News | Ionis Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Announced the Pivotal Phase 3 Study Design Following Alignment With the FDA on ION582 for Angelman Syndrome